Metrics to compare | ENZC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipENZCPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −2.9x | −0.5x | |
PEG Ratio | 0.00 | −0.06 | 0.00 | |
Price/Book | 0.0x | 1.9x | 2.6x | |
Price / LTM Sales | 0.0x | 188.8x | 3.0x | |
Upside (Analyst Target) | 0.0% | 210.5% | 58.6% | |
Fair Value Upside | Unlock | 17.8% | 10.2% | Unlock |
Enzolytics, Inc. a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company’s proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics, Inc. is based in Plano, Texas.